Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1992 2
1993 5
1994 5
1995 2
1996 1
1997 7
1998 7
1999 5
2000 5
2001 3
2002 2
2003 5
2004 6
2005 4
2006 11
2007 2
2008 7
2009 5
2010 5
2011 8
2012 7
2013 19
2014 12
2015 19
2016 14
2017 11
2018 21
2019 20
2020 22
2021 30
2022 15
Text availability
Article attribute
Article type
Publication date

Search Results

266 results
Results by year
Filters applied: . Clear all
Page 1
Trial of Anifrolumab in Active Systemic Lupus Erythematosus.
Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, Bae SC, Brohawn PZ, Pineda L, Berglind A, Tummala R; TULIP-2 Trial Investigators. Morand EF, et al. N Engl J Med. 2020 Jan 16;382(3):211-221. doi: 10.1056/NEJMoa1912196. Epub 2019 Dec 18. N Engl J Med. 2020. PMID: 31851795 Clinical Trial.
Stress-glucocorticoid-TSC22D3 axis compromises therapy-induced antitumor immunity.
Yang H, Xia L, Chen J, Zhang S, Martin V, Li Q, Lin S, Chen J, Calmette J, Lu M, Fu L, Yang J, Pan Z, Yu K, He J, Morand E, Schlecht-Louf G, Krzysiek R, Zitvogel L, Kang B, Zhang Z, Leader A, Zhou P, Lanfumey L, Shi M, Kroemer G, Ma Y. Yang H, et al. Among authors: morand e. Nat Med. 2019 Sep;25(9):1428-1441. doi: 10.1038/s41591-019-0566-4. Epub 2019 Sep 9. Nat Med. 2019. PMID: 31501614
Treatment Update in Systemic Lupus Erythematous.
Hoi AY, Morand EF. Hoi AY, et al. Among authors: morand ef. Rheum Dis Clin North Am. 2021 Aug;47(3):513-530. doi: 10.1016/j.rdc.2021.04.012. Epub 2021 Jun 10. Rheum Dis Clin North Am. 2021. PMID: 34215377 Review.
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force.
van Vollenhoven RF, Mosca M, Bertsias G, Isenberg D, Kuhn A, Lerstrøm K, Aringer M, Bootsma H, Boumpas D, Bruce IN, Cervera R, Clarke A, Costedoat-Chalumeau N, Czirják L, Derksen R, Dörner T, Gordon C, Graninger W, Houssiau F, Inanc M, Jacobsen S, Jayne D, Jedryka-Goral A, Levitsky A, Levy R, Mariette X, Morand E, Navarra S, Neumann I, Rahman A, Rovensky J, Smolen J, Vasconcelos C, Voskuyl A, Voss A, Zakharova H, Zoma A, Schneider M. van Vollenhoven RF, et al. Among authors: morand e. Ann Rheum Dis. 2014 Jun;73(6):958-67. doi: 10.1136/annrheumdis-2013-205139. Epub 2014 Apr 16. Ann Rheum Dis. 2014. PMID: 24739325 Free article.
Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus.
He J, Zhang X, Wei Y, Sun X, Chen Y, Deng J, Jin Y, Gan Y, Hu X, Jia R, Xu C, Hou Z, Leong YA, Zhu L, Feng J, An Y, Jia Y, Li C, Liu X, Ye H, Ren L, Li R, Yao H, Li Y, Chen S, Zhang X, Su Y, Guo J, Shen N, Morand EF, Yu D, Li Z. He J, et al. Among authors: morand ef. Nat Med. 2016 Sep;22(9):991-3. doi: 10.1038/nm.4148. Epub 2016 Aug 8. Nat Med. 2016. PMID: 27500725
Definition and initial validation of a Lupus Low Disease Activity State (LLDAS).
Franklyn K, Lau CS, Navarra SV, Louthrenoo W, Lateef A, Hamijoyo L, Wahono CS, Chen SL, Jin O, Morton S, Hoi A, Huq M, Nikpour M, Morand EF; Asia-Pacific Lupus Collaboration. Franklyn K, et al. Among authors: morand ef. Ann Rheum Dis. 2016 Sep;75(9):1615-21. doi: 10.1136/annrheumdis-2015-207726. Epub 2015 Oct 12. Ann Rheum Dis. 2016. PMID: 26458737
266 results